SOCS3
炎症
生物
细胞因子
车站3
STAT蛋白
信号转导
免疫学
白细胞介素10
细胞生物学
癌症研究
作者
Soraya Taleb,Mélissa Romain,Bhama Ramkhelawon,Catherine Uyttenhove,Gerard Pasterkamp,Olivier Herbin,Bruno Esposito,Nicolas Pérez,Hideo Yasukawa,Jacques Van Snick,Akihiko Yoshimura,Alain Tedgui,Ziad Mallat
摘要
Atherosclerosis is an inflammatory vascular disease responsible for the first cause of mortality worldwide. Recent studies have clearly highlighted the critical role of the immunoinflammatory balance in the modulation of disease development and progression. However, the immunoregulatory pathways that control atherosclerosis remain largely unknown. We show that loss of suppressor of cytokine signaling (SOCS) 3 in T cells increases both interleukin (IL)-17 and IL-10 production, induces an antiinflammatory macrophage phenotype, and leads to unexpected IL-17–dependent reduction in lesion development and vascular inflammation. In vivo administration of IL-17 reduces endothelial vascular cell adhesion molecule–1 expression and vascular T cell infiltration, and significantly limits atherosclerotic lesion development. In contrast, overexpression of SOCS3 in T cells reduces IL-17 and accelerates atherosclerosis. We also show that in human lesions, increased levels of signal transducer and activator of transcription (STAT) 3 phosphorylation and IL-17 are associated with a stable plaque phenotype. These results identify novel SOCS3-controlled IL-17 regulatory pathways in atherosclerosis and may have important implications for the understanding of the increased susceptibility to vascular inflammation in patients with dominant-negative STAT3 mutations and defective Th17 cell differentiation.
科研通智能强力驱动
Strongly Powered by AbleSci AI